secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2026-06-29T20:07:30+00:00
Accession:  0001104659-26-078823
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma reduces ATM capacity to $5M and suspends sales under Leerink agreement
--------------------------------------------------------------------------------

- On June 29, 2026, Nuvectis lowered the amount available for sale under the Sales Agreement Prospectus to $5 million.
- The company is suspending the Sales Agreement Prospectus and will not sell any shares until a new prospectus or registration statement is filed.
- The Sales Agreement with Leerink Partners LLC remains in full force and effect; only the current offering is paused.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/0001104659-26-078823-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926078823/tm2618981d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-078823

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer